Exits, 7/10/2026

How we did on the trades we exited this week.

This Week’s Trade Exits

As soon as I exit a trade, I note that in the comments of the post where I first mentioned the trade; at the end of the week, I try to track them all in one post. Starting in July, 2024, I have also been tracking them in a spreadsheet. These are the trades I exited this week.

Stocks or Exchange Traded Products

1. Shares of Sivers Semiconductors (SIVEF). Bought for $2.24 on 4/15/2026; sold half for $6.75 on 5/14/2026; sold one-third of the remaining shares for $7.61 on 5/28/2026; sold the remaining shares for $4.20 on 7/8/2026. Profit: 170%. Signal: Market Watchers.

Options

1. Put spread on Cemex (CX 0.00%↑). Entered at a net credit of $0.47 as part of a 4-leg hybrid combo on 2/24/2026; exited at a net debit of $0.12 on 7/10/2026. Profit: 74% on premium collected (23% on max risk). Signal: PA Top Names.

2. Put spread on BlackBerry (BB 0.00%↑). Entered at a net credit of $0.61 as part of a 3-leg combo on 5/20/2026; exited at a net debit of $0.12 on 7/6/2026. Profit: 80% on premium collected (55% on max risk). Signal: Market Watchers.

3. Call calendar on uniQure (QURE 0.00%↑). Entered at a net debit of $5.57 as part of a 4-leg hybrid combo on 6/5/2026; exited at a net credit of $10.00 on 7/8/2026. Profit: 80%. Signal: Multibaggers.

4. Put spread on Ovintiv (OVV 0.00%↑). Entered at a net credit of $1.14 as part of a 4-leg hybrid combo on 4/16/2026; exited at a net debit of $0.20 on 7/7/2026. Profit: 82% on premium collected (24% on max risk). Signal: Chartmill.

5. Put spread on Calumet (CLMT 0.00%↑). Entered at a net credit of $1.08 as part of a 4-leg hybrid combo on 5/1/2026; exited at a net debit of $0.20 on 7/10/2026. Profit: 81% on premium collected (22% on max risk). Signal: PA Top Names.

6. Short call on Fluence Energy (FLNC 0.00%↑). Sold-to-open for $2.45 as part of a 4-leg hybrid combo on 6/12/2026; bought-to-close for $0.20 on 7/8/2026. Profit: 92% on premium collected. Signal: Market Watchers.

7. Put spread on Bioventus (BVS 0.00%↑). Entered at a net credit of $1.71 as part of a 4-leg hybrid combo on 3/18/2026; exited at a net debit of $0.20 on 7/6/2026. Profit: 88% on premium collected (191% on max risk). Signal: Chartmill.

8. Short call on AstraZeneca (AZN 0.00%↑). Sold-to-open the September 18th, 2026 $230 call for $5.14 as part of a 4-leg hybrid combo on 4/16/2026; bought-to-close that call for $0.20 on 7/10/2026. Profit: 96% on premium collected. Signal: PA Top Names.

9. 4-leg hybrid combo on Twist Bioscience (TWST 0.00%↑). Entered at a net debit of $2.25 on 2/27/2026; exited the July 17, 2026 $45/$40 put spread at a net debit of $0.20 on 6/4/2026; exited the October 16, 2026 $57.50 / short July 17, 2026 $65 call calendar at a net credit of $10.00 on 7/6/2026. Profit: 336% on premium outlay (104% on max risk). Signal: Multibaggers.

10. 4-leg hybrid combo on GlobalFoundries (GFS 0.00%↑). Entered at a net debit of $2.40 on 3/3/2026; exited the July 17, 2026 $45/$40 put spread at a net debit of $0.20 on 5/5/2026; exited the call calendar at a net credit of $13.50 on 7/9/2026. Profit: 454% on net debit (147% on max risk). Signal: Multibaggers.

11. 4-leg hybrid combo on Moderna (MRNA 0.00%↑). Entered at a net debit of $1.15 on 4/7/2026; exited the July 17, 2026 $42/$37 put spread at a net debit of $0.20 on 6/17/2026; exited the call calendar at a net credit of $7.00 on 7/10/2026. Profit: 491% on net debit (92% on max risk). Signal: PA Top Names.

12. 3-leg combo on Opera (OPRA 0.00%↑). Entered at a net debit of $0.75 on 12/1/2025; exited the April 17, 2026 $12.50/$10 put spread at a net credit of $0.15 on 2/27/2026; sold half of the July 17, 2026 $15 calls for $4.50 on 5/4/2026; sold the remaining half for $5.40 on 7/6/2026. Profit: 580% on premium outlay (134% on max risk). Signal: Chartmill

Comments

Stocks or Exchange Traded Products

Our lone stock exit was Sivers Semiconductors, which we bought at $2.24 in April because it has no listed options. We sold it in tranches: half at $6.75 in May, a third of the remainder at $7.61 two weeks later, and the rest at $4.20 this week, for a blended 170% gain. The tranche discipline captured most of the spike; holding the last piece for more cost us some of it as the stock faded. SIVEF is back on our watchlist after recent insider buying, but the chart needs repair before we’d reenter.

Options

A Clean Sweep

All twelve options exits this week were profitable. That won’t happen every week—losers tend to collect at expirations, and July OpEx is next Friday—but this list shows the machine working end to end: put spreads harvested near their floors, short calls bought back after collecting most of their premium, and four full combos closed at multiples of their cost.

The Calendar Harvest

Four exits came from the same maneuver. When a stock runs through both call strikes in one of our hybrids, the standing $0.20 order to buy back the short call stops being realistic, so we cancel it and sell the calendar—both call legs together—near its maximum value. That’s how uniQure (80%), Twist Bioscience (336% on premium outlay), GlobalFoundries (454% on net debit), and Moderna (491%) closed. Moderna shows the arithmetic cleanly: we entered the combo for a $1.15 net debit in April, paid $0.20 to exit the put spread in June, and sold the calendar for $7.00 this week.

Short Calls Bought Back, Upside Uncapped

We bought back short calls on AstraZeneca (96% on premium collected) and Fluence Energy (92%), leaving our October $220 AZN call and November $31 FLNC call uncapped. The put spread exits on Cemex and Calumet did the same kind of work from the other side: the financing legs closed at or below our standard $0.20 exit, while the four October $14 CX calls and the Calumet call calendar stay on. We also posted GTC sell targets on five of our uncapped long calls this week, in the comments under their trade alerts and via chat/email.

Opera’s Long Tail

The Opera combo, opened in early December, posted this week’s best number: 580% on premium outlay. We closed the put spread back in February, sold half of the July $15 calls at $4.50 in May, and sold the other half at $5.40 this week, eleven days before they would have expired.

Thirteen exits, thirteen winners. Same process throughout: define the risk at entry, let the short legs help pay for the trade, and give the long calls room to work.